
IthaID: 810
Names and Sequences
Functionality: | Globin gene causative mutation | Pathogenicity: | Benign / Likely Benign |
---|---|---|---|
Common Name: | CD 6 GAG>AAG [Glu>Lys] | HGVS Name: | HBB:c.19G>A |
Hb Name: | HbC | Protein Info: | β 6(A3) Glu>Lys |
Context nucleotide sequence:
AGACACCATGGTGCATCTGACTCCT [A/C/G] AGGAGAAGTCTGCCGTTACTGCCCT (Strand: -)
Protein sequence:
MVHLTPKEKSAVTALWGKVNVDEVGGEALGRLLVVYPWTQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFATLSELHCDKLHVDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH
Also known as:
We follow the HGVS sequence variant nomenclature and IUPAC standards.
Phenotype
Hemoglobinopathy Group: | Structural Haemoglobinopathy |
---|---|
Hemoglobinopathy Subgroup: | β-chain variant |
Allele Phenotype: | N/A |
Stability: | N/A |
Oxygen Affinity: | N/A |
Associated Phenotypes: | Haemolytic anaemia [HP:0001878] |
Location
Chromosome: | 11 |
---|---|
Locus: | NG_000007.3 |
Locus Location: | 70613 |
Size: | 1 bp |
Located at: | β |
Specific Location: | Exon 1 |
Other details
Type of Mutation: | Point-Mutation(Substitution) |
---|---|
Effect on Gene/Protein Function: | Missense codons (Protein Structure) |
Ethnic Origin: | African |
Molecular mechanism: | Altered secondary structure |
Inheritance: | Recessive |
DNA Sequence Determined: | Yes |
HPLC
Disclaimer: The HPLC images are provided as an information resource only.
Bio-Rad Laboratories, Inc and the ITHANET Portal disclaim responsibility and have no liability if this information is used for diagnostic or treatment purposes.
D-10™ and VARIANT™ are registered trademarks of Bio-Rad Laboratories, Inc. and used with permission.
Redistribution and use of the above material is allowed only with permission by Bio-Rad Laboratories, Inc.
To access HPLC images and reports for different variants, use the IthaChrom tool.
ID | Hb Variant | Gene | Instrument | Method | Area (%) | Ret Time (min) | Comments | ||
---|---|---|---|---|---|---|---|---|---|
14 | HbC | β | D-10 | Dual Kit Program | 82.5 | 4.82 | Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal. | [PDF] | |
32 | HbC | β | D-10 | HbA1c Program | 46.5 | 1.77 | Heterozygote | [PDF] | |
34 | HbC | β | D-10 | HbA1c Program | 89 | 1.76 | Homozygote; HbC homozygote does not lead to a thal intermedia but to a mild microcytic anemia. | [PDF] | |
258 | HbC | β | D-10 | Dual Kit Program | 26 | 4.7 | Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis. | [PDF] | |
265 | HbC | β | D-10 | Dual Kit Program | 32.3 | 4.7 | heterozygote | [PDF] | |
361 | HbC | β | D-10 | Dual Kit Program | 75.5 | 4.69 | HbC homozygous or compound heterozygous with beta zero thalassaemia. | [PDF] | |
413 | HbC | β | D-10 | Dual Kit Program | 79.3 | 4.69 | Homozygote. | [PDF] | |
488 | HbC | β | D-10 | Dual Kit Program | 29.6 | 4.7 | compounnd heterozygote for HbC and Hb Korle Bu | [PDF] | |
509 | HbC | β | D-10 | Dual Kit Program | 46.4 | 4.7 | Compound heterozygote for HbS and HbC | [PDF] | |
518 | HbC | β | D-10 | Dual Kit Program | 46.3 | 4.7 | Compound heterozygote for HbS and HbC | [PDF] | |
520 | HbC | β | D-10 | Dual Kit Program | 46.3 | 5.12 | Compound heterozygote for HbS and HbC | [PDF] | |
528 | HbC | β | D-10 | Dual Kit Program | 43.6 | 4.71 | Compound heterozygote for HbS and HbC | [PDF] | |
542 | HbC | β | D-10 | Dual Kit Program | 50.4 | 4.7 | Compound heterozygote for HbC and (delta-beta) zero thalassaemia. | [PDF] | |
546 | HbC | β | D-10 | Dual Kit Program | 59.4 | 4.7 | heterozygote | [PDF] | |
568 | HbC | β | D-10 | Dual Kit Program | 48.1 | 4.79 | Compound heterozygote for HbC and Hb O-Arab. | [PDF] | |
15 | HbC | β | VARIANT | β-thal Short Program | 84.2 | 5.09 | Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal. | [PDF] | |
259 | HbC | β | VARIANT | β-thal Short Program | 23.8 | 5.03 | Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis. | [PDF] | |
266 | HbC | β | VARIANT | β-thal Short Program | 37.6 | 4 | heterozygote | [PDF] | |
362 | HbC | β | VARIANT | β-thal Short Program | 79.4 | 5.06 | HbC homozygous or compound heterozygous with beta zero thalassaemia. | [PDF] | |
414 | HbC | β | VARIANT | β-thal Short Program | 82.3 | 5.06 | Homozygote. | [PDF] | |
489 | HbC | β | VARIANT | β-thal Short Program | 32 | 5.1 | compound heterozygote for HbC and Hb Korle Bu | [PDF] | |
492 | HbC | β | VARIANT | β-thal Short Program | 29.9 | 5.11 | Compound heterozygote for HbC and HbS. Recently transfused. | [PDF] | |
511 | HbC | β | VARIANT | β-thal Short Program | 45.8 | 5.1 | Compound heterozygote for HbC and HbS | [PDF] | |
530 | HbC | β | VARIANT | β-thal Short Program | 45.9 | 5.11 | Compound heterozygote for HbS and HbC | [PDF] | |
543 | HbC | β | VARIANT | β-thal Short Program | 61.1 | 5.1 | Compound heterozygote for HbC and (delta-beta) zero thalassaemia. | [PDF] | |
547 | HbC | β | VARIANT | β-thal Short Program | 62 | 5.1 | Compound heterozygote for HbC and beta-thalassaemia. | [PDF] | |
570 | HbC | β | VARIANT | β-thal Short Program | 47.7 | 5.12 | Compound heterozygote for HbC and Hb O-Arab. | [PDF] | |
16 | HbC | β | VARIANT II | β-thal Short Program | 86.8 | 5.16 | Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal. | [PDF] | |
17 | HbC | β | VARIANT II | Dual Kit Program | 82.3 | 4.42 | Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal. | [PDF] | |
33 | HbC | β | VARIANT II | HbA1c Program | 37.1 | 2.11 | Heterozygote | [PDF] | |
35 | HbC | β | VARIANT II | HbA1c Program | 97 | 2.1 | Homozygote; HbC homozygote does not lead to a thal intermedia but to a mild microcytic anemia. | [PDF] | |
40 | HbC | β | VARIANT II | Dual Kit Program - HbA1c | 41.7 | 2.04 | heterozygote | [PDF] | |
260 | HbC | β | VARIANT II | β-thal Short Program | 25.1 | 5.11 | Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis. | [PDF] | |
261 | HbC | β | VARIANT II | Dual Kit Program | 24.9 | 4.438 | Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis. | [PDF] | |
267 | HbC | β | VARIANT II | β-thal Short Program | 33.9 | 5.17 | heterozygote | [PDF] | |
268 | HbC | β | VARIANT II | Dual Kit Program | 32.2 | 4.433 | heterozygote | [PDF] | |
363 | HbC | β | VARIANT II | β-thal Short Program | 18.5 | 4.86 | [PDF] | ||
364 | HbC | β | VARIANT II | Dual Kit Program | 74.8 | 4.41 | Homozygous. | [PDF] | |
415 | HbC | β | VARIANT II | β-thal Short Program | 85.4 | 5.13 | Homozygote. | [PDF] | |
416 | HbC | β | VARIANT II | Dual Kit Program | 78.9 | 4.416 | Homozygote. | [PDF] | |
513 | HbC | β | VARIANT II | Dual Kit Program | 42.7 | 4.422 | Compound heterozygote for HbC and HbS | [PDF] | |
522 | HbC | β | VARIANT II | Dual Kit Program | 43.2 | 4.431 | Compound heterozygote for HbS and HbC. | [PDF] | |
532 | HbC | β | VARIANT II | β-thal Short Program | 44.6 | 5.17 | Compound heterozygote for HbS and HbC | [PDF] | |
534 | HbC | β | VARIANT II | Dual Kit Program | 40.8 | 4.423 | Compound heterozygote for HbS and HbC | [PDF] | |
544 | HbC | β | VARIANT II | β-thal Short Program | 60.5 | 5.15 | Compound heterozygote for HbC and (delta-beta) zero thalassaemia. | [PDF] | |
545 | HbC | β | VARIANT II | Dual Kit Program | 50 | 4.414 | Compound heterozygote for HbC and (delta-beta) zero thalassaemia. | [PDF] | |
548 | HbC | β | VARIANT II | β-thal Short Program | 61.8 | 5.16 | Compound heterozygote for HbC and beta-thalassaemia. | [PDF] | |
549 | HbC | β | VARIANT II | Dual Kit Program | 59.3 | 4.422 | Compound heterozygote for HbC and beta-thalassaemia. | [PDF] | |
572 | HbC | β | VARIANT II | β-thal Short Program | 47.7 | 5.15 | Compound heterozygote for HbC and Hb O-Arab. | [PDF] | |
574 | HbC | β | VARIANT II | Dual Kit Program | 43.8 | 4.419 | Compound heterozygosity for HbC and Hb O Arab. | [PDF] |
In silico pathogenicity prediction
Note:
The impact thresholds provided in this section are based on the analyses performed in Tamana et.al. For any given tool, the impact thresholds defined for the set of variants with the same effect on function as the variant examined, are preferred over those defined for the full dataset.
Frequencies
Publications / Origin
- ITANO HA, NEEL JV, A new inherited abnormality of human hemoglobin., Proc. Natl. Acad. Sci. U.S.A. , 36(11), 613-7, 1950
- NEEL JV, KAPLAN E, ZUELZER WW, Further studies on hemoglobin C. I. A description of three additional families segregating for hemoglobin C and sickle cell hemoglobin., Blood , 8(8), 724-34, 1953
- RANNEY HM, LARSON DL, McCORMACK GH, Some clinical, biochemical and genetic observations on hemoglobin C., J. Clin. Invest. , 32(12), 1277-84, 1953
- HUNT JA, INGRAM VM, A terminal peptide sequence of human haemoglobin?, Nature , 184(0), 640-1, 1959
- SMITH EW, KREVANS JR, Clinical manifestations of hemoglobin C disorders., Bull Johns Hopkins Hosp , 104(1), 17-43, 1959
- BAGLIONI C, INGRAM VM, Four adult haemoglobin types in one person., Nature , 189(0), 465-7, 1961
- Fabry ME, Kaul DK, Raventos C, Baez S, Rieder R, Nagel RL, Some aspects of the pathophysiology of homozygous Hb CC erythrocytes., J. Clin. Invest. , 67(5), 1284-91, 1981
- Boehm CD, Dowling CE, Antonarakis SE, Honig GR, Kazazian HH, Evidence supporting a single origin of the beta(C)-globin gene in blacks., Am. J. Hum. Genet. , 37(4), 771-7, 1985
- Fischel-Ghodsian N, Hirsch PC, Bohlman MC, Rapid detection of the hemoglobin C mutation by allele-specific polymerase chain reaction., Am. J. Hum. Genet. , 47(6), 1023-4, 1990
- Trabuchet G, Elion J, Dunda O, Lapouméroulie C, Ducrocq R, Nadifi S, Zohoun I, Chaventre A, Carnevale P, Nagel RL, Nucleotide sequence evidence of the unicentric origin of the beta C mutation in Africa., Hum. Genet. , 87(5), 597-601, 1991
- Agarwal A, Guindo A, Cissoko Y, Taylor JG, Coulibaly D, Koné A, Kayentao K, Djimde A, Plowe CV, Doumbo O, Wellems TE, Diallo D, Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S., Blood , 96(7), 2358-63, 2000
- Modiano D, Luoni G, Sirima BS, Simporé J, Verra F, Konaté A, Rastrelli E, Olivieri A, Calissano C, Paganotti GM, D'Urbano L, Sanou I, Sawadogo A, Modiano G, Coluzzi M, Haemoglobin C protects against clinical Plasmodium falciparum malaria., Nature , 414(6861), 305-8, 2001
- Rihet P, Flori L, Tall F, Traore AS, Fumoux F, Hemoglobin C is associated with reduced Plasmodium falciparum parasitemia and low risk of mild malaria attack., Hum. Mol. Genet. , 13(1), 1-6, 2004
- Modiano D, Bancone G, Ciminelli BM, Pompei F, Blot I, Simporé J, Modiano G, Haemoglobin S and haemoglobin C: 'quick but costly' versus 'slow but gratis' genetic adaptations to Plasmodium falciparum malaria., Hum. Mol. Genet. , 17(6), 789-99, 2008
- Gouagna LC, Bancone G, Yao F, Yameogo B, Dabiré KR, Costantini C, Simporé J, Ouedraogo JB, Modiano D, Genetic variation in human HBB is associated with Plasmodium falciparum transmission., Nat. Genet. , 42(4), 328-31, 2010
- Cyrklaff M, Sanchez CP, Kilian N, Bisseye C, Simpore J, Frischknecht F, Lanzer M, Hemoglobins S and C interfere with actin remodeling in Plasmodium falciparum-infected erythrocytes., Science , 334(6060), 1283-6, 2011
Created on 2010-06-16 16:13:16,
Last reviewed on 2014-04-15 19:17:44 (Show full history)
A/A | Date | Curator(s) | Comments |
---|---|---|---|
1 | 2010-06-16 16:13:16 | The IthaGenes Curation Team | Created |
2 | 2013-10-15 17:00:14 | The IthaGenes Curation Team | Reviewed. |
3 | 2014-04-15 16:16:06 | The IthaGenes Curation Team | Reviewed. Added references. |
4 | 2014-04-15 16:25:49 | The IthaGenes Curation Team | Reviewed. Added ClinVar link; corrected common name. |
5 | 2014-04-15 19:17:44 | The IthaGenes Curation Team | Reviewed. Corrected strand. |
Disclaimer: The information on this website is provided as an information resource only
and must not to be used as a substitute for professional diagnosis and treatment.
The ITHANET Portal and IthaGenes are not responsible or liable for any advice, course of treatment,
diagnosis or any other information, services or products that an individual obtains through this website.
IthaGenes was last updated on 2023-11-27 17:32:30